DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like
Genentech
○
Search Organization
,
Allogene Therapeutics
○
Search Organization
, and
Merck & Co. Inc
○
Search Organization
. Promising therapies such as
Atezolizumab
○
Search Drug
and
ALLO-316
○
Search Drug
are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like
ADI-270
○
Search Drug
and
AB-2100
○
Search Drug
.